Related Experiment Video
Updated: Jun 28, 2025

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
Published on: May 16, 2025
Prostaglandin E-induced polycyclic cutaneous eruption with geometric features
Ananya Shah1, Jinia El-Feghaly1, Alexandra M Bender1
1Department of Dermatology, University of Rochester, Rochester, New York, USA.
Insights
Prostaglandin E1 (PGE1) is crucial for infants with congenital heart disease (CHD). A case study shows a rash from PGE1 can resolve with reduced dosage, potentially allowing continued treatment.
Area of Science:
- Neonatal cardiology
- Pediatric pharmacology
- Dermatology
Background:
- Prostaglandin E1 (PGE1) maintains patency of the ductus arteriosus.
- PGE1 is vital for ductus-dependent congenital heart disease (CHD) management.
- Infants with specific CHDs require PGE1 to ensure pulmonary blood flow or proper great artery positioning.
Observation:
- A neonate receiving PGE1 for CHD developed a distinct rash.
- The rash presented as bright erythematous annular and polycyclic patches.
- The dermatological reaction appeared on day 2 of PGE1 administration.
Findings:
- Reducing the PGE1 dosage led to spontaneous resolution of the rash.
- The observed rash is a potential side effect of PGE1 treatment.
- The case suggests PGE1 therapy may not always require interruption due to skin reactions.
Implications:
- This finding could inform clinical management of PGE1 side effects.
- It highlights the possibility of continuing essential PGE1 treatment with dosage adjustments.
- Further investigation into PGE1-induced dermatological reactions in neonates is warranted.
Abstract:
Prostaglandin E1 (PGE1) is a substance produced by the patent ductus arteriosus that keeps it open. PGE1 can be a lifesaving drug for infants born with ductus-dependent congenital heart disease (CHD) where there is a block of blood flow to the lungs or transposition of great arteries. We present a case of a 36-week, 2-day gestation neonate with CHD who developed bright erythematous annular and polycyclic patches on day 2 of PGE1 administration. When PGE1 dosing was decreased, the rash resolved on its own. Our case demonstrates that PGE1 treatment may not need to be interrupted.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...

